Abstract
A 2½-year-old boy developed optic atrophy during an 11-month course of diiodohydroxyquin (Diodoquin) administration. This drug is currently used for several diarrheal conditions. Iodochlorhydroxyquin (Vioform), a congener of Diodoquin, has recently been implicated as the cause of subacute myelo-optic neuropathy (SMON). Attention is drawn to the possible neurotoxic and retinotoxic effects of Diodoquin. Current recommendations concerning the use of halogenated hydroxyquinolines should be reevaluated in light of these data.
- Copyright © 1974 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.